<DOC>
	<DOCNO>NCT00089999</DOCNO>
	<brief_summary>This phase II study evaluate compare efficacy tolerability two dose schedule ( 1500 mg QD 500 mg BID ) oral Lapatinib treatment patient advance metastatic breast cancer .</brief_summary>
	<brief_title>Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm invasive breast cancer incurable stage IIIB , IIIC T4 lesion stage IV disease primary diagnosis relapse curative intent surgery . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Documented amplification ErbB2 Fluorescence situ hybridization ( FISH ) Measurable disease Response Evaluation Criteria In Solid Tumors ( RECIST ) Adequate renal , hepatic cardiac function Exclusion criterion : Prior chemotherapy , immunotherapy , biologic therapy antiErbB1/ErbB2 therapy adjuvant therapy . [ Prior neoadjuvant adjuvant therapy ( include trastuzumab ) allow provide stop least 12 month study entry . Patients active brain metastasis Patients bilateral breast cancer , bone metastasis disease site metastasis 30 % hepatic parenchyma .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>lapatinib</keyword>
	<keyword>advanced</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>GW572016</keyword>
	<keyword>ErbB2</keyword>
</DOC>